Table 1.
Characteristics of therapeutic, interventional clinical trials involving the usage of iPSCs worldwide, 2021.1
| Trial ID | Title | Phase | Type of cell | Condition | Country | Target size | Sponsor |
|---|---|---|---|---|---|---|---|
| NCT04396899 | Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure | N/A | Allogeneic | Heart Failure | Germany | 6 | University Medical Center Goettingen |
| NCT04696328 | Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic | N/A | Allogeneic | Myocardial ischemia | Japan | 4 | Osaka University |
| NCT03763136 | The Study of Human Epicardial Injection With Allogenic Induced Pluripotent Stem Cell-derived Cardiomyocytes in Ischemic Heart Failure | N/A | Allogeneic | Heart failure | China | 48 | Nanjing University Medical School |
| NCT04537351 | A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With COVID-19 | I | Allogeneic | Covid19 – Acute Respiratory Distress Syndrome | Australia | 10 | Cynata Therapeutics Limited |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1) | I | Allogeneic | Cancers/Tumors | US | 40 | Fate Therapeutics |
| NCT04363346 | Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia | I | Allogeneic | COVID-19 | US | 40 | Masonic Cancer Center |
| NCT02923375 | An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease | N/A | Allogeneic | Graft vs Host Disease | Australia | 19 | Cynata Therapeutics Limited |
| NCT04630769 | Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | I | Allogeneic | Ovarian Cancer, fallopian tube adenocarcinoma, primary peritoneal cavity cancer | US | 100 | Masonic Cancer Center |
| JPRN-JMA-IIA00384 | Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease | I, II | Allogeneic | Parkinson's disease | Japan | 7 | Kyoto University Hospital |
| JPRN-JMA-IIA00385 | Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease | III | Allogeneic | Parkinson's disease | Japan | 7 | Kyoto University Hospital |
| JPRN-jRCTa031190228 | Regenerative medicine using iPS cell-derived neural progenitor cells for subacute spinal cord injury | I, II | Allogeneic | Spinal cord injury at subacute stage | Japan | 4 | Keio University |
| JPRN-jRCTa032200189 | Safety study of allogeneic iPS cell-derived regenerated myocardial cell transplantation in patients with refractory severe heart failure | I, II | Allogeneic | Severe heart failure patients with NYHA class III or higher (HFrEF by Dilated Cardiomyopathy) | Japan | 3 | Keio University |
| JPRN-jRCTa050200027 | Clinical study on allogeneic iPS cell-derived retinal sheet transplantation for retinitis pigmentosa | I | Allogeneic | Retinitis pigmentosa | Japan | 2 | Kobe City Eye Hospital |
| JPRN-UMIN000026003 | A Study of transplantation of allogenic induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell suspension in subjects with neovascular age-related macular degeneration | N/S | Allogeneic | Neovascular age-related macular degeneration | Japan | 5 | Kobe City Eye Hospital |
| JPRN-UMIN000030084 | Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease | I, II | Allogeneic | Neuroinflammatory disorder, Parkinson’s disease, brain tumor | Japan | 12 | Kyoto University |
| NCT04339764 | A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration | I, II | Autologous | Age-Related Macular Degeneration | US | 200 | NIH Clinical Center |
| JPRN-jRCTa050190117 | Clinical study on autotransfusion of iPS cell-derived platelets for thrombocytopenia | I | Autologous | Aplastic anemia with platelet transfusion refractoriness due to anti-platelet alloantibodies | Japan | 1 | Kyoto University Hospital |
| JPRN-UMIN000011929 | A Study of transplantation of autologous induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell sheet in subjects with exudative age-related macular degeneration | N/S | Autologous | Exudative age-related macular degeneration | Japan | 6 | Kobe City Eye Hospital |
| IRCT20200429047241N1 | Personalized Immunology of Patients with Advanced Breast Cancer Using induced Pluripotent Stem Cell-Derived Natural Killer cells | I | Autologous | Breast cancer | Iran | 32 | Tehran University of Medical Science |